Li Jieqiong, Yuan Xuefeng, Peng Jie, Hou Xingfang, Zheng Fang, Xiao Gang, Liu Xiaohui
Department of Pediatric, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China.
Department of Nosocomial Infection Management, The First Hospital of Changsha (The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University), Changsha, Hunan, People's Republic of China.
Infect Drug Resist. 2024 Nov 29;17:5305-5313. doi: 10.2147/IDR.S485232. eCollection 2024.
The World Health Organization (WHO) declared Human Monkeypox (mpox) as a public health emergency of international concern (PHEIC) in July 2022. Due to border quarantine and isolation measures implemented from January 2020 to December 2022, Beijing did not report its first locally transmitted case of mpox until May 31, 2023, which represented a delayed occurrence compared to other countries. The aim of this observational analysis is to describe demographical data, symptoms presentation and clinical course till outcome of patients diagnosed with monkeypox (mpox) from June to December 2023 at a tertiary level hospital in Changsha, china.
We conducted a retrospective study on 44 confirmed mpox cases and compared laboratory data between HIV-infected and non-HIV-infected patients at a tertiary general hospital in Changsha, China.
All patients were male, with a median age of 33 years. 88.6% patients had sex with men (MSM), and 88.9% HIV-infected patients accepted antiretroviral therapy (ART). The early symptoms of mpox typically include rashes and fever, which usually appear around the penis or anus. There were significant differences were found between HIV-infected and non-HIV-infected patients in laboratory data (P < 0.05), but none were clinically significant.
This study underscores the importance of targeted mpox management strategies in MSM populations, particularly those co-infected with HIV and syphilis. Health authorities should consider proactive prevention and control measures, especially given the overlapping epidemics of HIV, syphilis, and mpox. Further studies are needed to explore the long-term clinical outcomes and potential benefits of vaccination in preventing mpox among high-risk populations.
世界卫生组织（WHO）于2022年7月宣布人类猴痘（mpox）为国际关注的突发公共卫生事件（PHEIC）。由于2020年1月至2022年12月实施的边境检疫和隔离措施，北京直到2023年5月31日才报告首例本地传播的猴痘病例，与其他国家相比出现了延迟。本观察性分析的目的是描述2023年6月至12月在中国长沙一家三级医院诊断为猴痘（mpox）的患者的人口统计学数据、症状表现及直至结局的临床病程。
我们对44例确诊的猴痘病例进行了回顾性研究，并比较了中国长沙一家三级综合医院中感染HIV和未感染HIV患者的实验室数据。
所有患者均为男性，中位年龄33岁。88.6%的患者为男男性行为者（MSM），88.9%的HIV感染患者接受了抗逆转录病毒治疗（ART）。猴痘的早期症状通常包括皮疹和发热，通常出现在阴茎或肛门周围。感染HIV和未感染HIV的患者在实验室数据方面存在显著差异（P<0.05），但均无临床意义。
本研究强调了针对MSM人群，特别是合并感染HIV和梅毒的人群制定猴痘管理策略的重要性。卫生当局应考虑采取积极的预防和控制措施，尤其是鉴于HIV、梅毒和猴痘的流行重叠情况。需要进一步研究以探索高危人群接种疫苗预防猴痘的长期临床结局和潜在益处。
